Therefore, J12 has potential as new therapeutic agent targeting NF-κB and MAPK signaling pathway to ameliorate paclitaxel-induced peripheral neuropathic pain and decrease adverse reaction of anti-tumor drugs. This evidence concerns the gene NFKB1 and neoplasm.